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ABSTRACT  
Introduction:  It is a proven fact that almost all drugs carry the potential to produce undesirable effects in addition to the desired ones. 
Aim:  The aim of this study is to determine the prevalence, pattern and socio-demographic determinants of adverse drug reactions among 
patients on HAART attending clinics in hospitals in Imo State Nigeria.  
Methodology:  This was a hospital-based cross-sectional study carried out among HIV patients attending clinics in hospitals in Imo State.  The 
400 participants were selected using a multistage sampling technique.  Data was collected using an interviewer administered, semi-structured 
questionnaire and analyzed using EPI Info version 3:2:1. Chi-square and regression analysis was used to test association between variables. P-
value was set at ≤ 0.05. 
Results: The mean age of the participants was 41.7±3.0 years with a male to female ration of 1:2. The adherence level to HIV treatment was 
85.0%. The prevalence of ADRs in the last 1 year preceding the study was 13.7% and the common forms of ADR experienced by patients was 
Hematological symptoms (34%), GIT symptoms (21.8%) and skin manifestation (20.0%). Socio-demographic determinants of the occurrence of 
ADR among the participants were: age 50 years and above (OR: 9.28), female gender (OR: 2.55) and living in a rural area (OR: 4.47). 
Conclusion:  Though the prevalence of ADR reported in this study was low, there is need to increase the depth of knowledge among HIV 
patients in the State, monitor patients closely by care givers and find possible ways to increase adherence to HIV drugs which was not optimal 
among participants. 
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1.0 INTRODUCTION 
It is a proven fact that almost all drugs carry the potential to 
produce undesirable effects, in addition to the desired 
ones.1,2 Though most of those taking these drugs gain far 
more benefits than harm, a sizeable proportion of them still 
experience undesirable effects from the use of the medicines 
which occurs at recommended doses and frequencies.3  
These effects, which are known as adverse drug reactions 
(ADRs) raise concerns to both the clinician and client, adding 
to the cost of medical treatment and increase morbidity and 
mortality.4,5  Adverse drug reaction as defined by World 
Health Organization (WHO), is any response to a drug which 
is noxious and unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis, or 
therapy of disease, or for the modification of physiological 
function.6  It is also defined as an undesirable effect, 
reasonably associated with the use of the drug that may 
occur as a part of the pharmacological action of a drug or 
may be unpredictable in its occurrence.7  
ADRs are one of the leading causes of morbidity and 
mortality in health care settings.  Furthermore, in many 
countries ADRs rank among the top ten leading causes of 
mortality. 8,9,10 Generally it has been found that there is a 
poor record of reporting ADRs in most hospitals 
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worldwide.11,12  American Pharmaceutical System analyzed 
39 studies carried out over four decades and found that a 
total of 106,000 people died as a result of ADRs.13 Since the 
discovery of Human Immunodeficiency Virus (HIV) in 1981, 
there has been an increasing number of patients primarily 
due to the use of antiretroviral drugs, better diagnostic 
procedures and widespread awareness about the disease.  
The introduction of highly active antiretroviral therapy 
(HAART) in developed countries in the late 90s has been 
associated with a remarkable decrease in AIDS related 
mortality.  This decrease in mortality has changed the 
perspective of HIV infection from that of a rapid fatal disease 
to a chronic manageable infection.14, 15 Globally 36.9 million 
people were living with HIV in 2017 with about 21.7 million 
of them being on Antiretroviral treatment (ART), thereby 
giving a coverage of 59%.  Also 1.8 million new infections 
were reported in the same year under review.16 Current 
reports from National HIV/AIDS Indicator and Impact Survey 
(NAIIS) showed that HIV prevalence in Nigeria has decreased 
from previous estimates of 2.8% to 1.4% in March 2019 with 
about 1.9 million people still living with HIV among whom 
about one million of them were accessing antiretroviral 
therapy.17 
Antiretroviral therapy works by providing suppression of a 
patient’s viral load and restoring their Immune system, and 
about 6.6 million HIV/AIDs related deaths worldwide have 
been prevented as a result of ART use.18,19  Despite these 
benefits, associated with ART, which can only be achieved 
with high levels of adherence,10 ART is linked with the 
occurrence of varying levels of adverse drug reactions and 
toxicities  which is of great public health concern as it 
constitutes a threat to sustained success of HIV treatment.19, 
20 ADRs due to ART has been reported to occur most 
commonly during the beginning of treatment as noticed in 
most chronically administered drug.22-24 Several studies have 
shown that ADRs are associated with non-adherence to 
treatment, discontinuation of ART, treatment failure and 
disease progression due virologic failure and change in ART 
regimens.24-29 Thus understanding the pattern of occurrence 
and distribution of ADRs among HIV infected patients is 
imperative to optimally manage their disease, given the 
significant consequences of ADRs in this patient 
population.30  ADRs vary greatly from one individual to 
another and has been described as single symptoms (e.g. 
anaemia, headache, nausea, vomiting) or as symptoms 
involving organs and systems (e.g. dermatological, 
hematological, gastrointestinal reaction).  It can also be 
classified according to severity or intensity or duration or 
estimates using scales or absolute numbers.31,32  ARDs 
caused by antiretroviral drugs can range from mild 
presentation e.g. mild gastrointestinal disturbances to 
serious side effects which includes hematological disorders, 
hepatotoxicity, neurological disorders, dermatological 
disorders, musculoskeletal disorders and metabolic 
disorders among others.10,20, 30-36. 
Varying prevalence rates of ADRs has been reported from 
several studies world over, ranging from 6.45% in 
Nicaragua30 to as high as 94% in a study from Tehran, Iran.37 
Prevalence rates found in other studies were; 70% in 
Calabar, Nigeria20, 89.8% in Gonda, Ethiopia33, 61.2% in 
Sikasso, Mali32,  70.8% in Jush, Ethiopia36, 19.5% in Duala, 
Cameroon14 and 9.4% in Ghana38.  These wide variations in 
prevalence rates reported from several studies can be 
explained by several factors ranging from different 
methodologies used in the conduct of the studies to the 
environmental and host factors and type of drug regimen 
used by the patients.   
Thus the aim of this study is to assess the prevalence and 
pattern of the occurrence of ADRs among HIV patients on 
HAART and the socio-demographic factors associated with 
the occurrence of ADRs irrespective of duration of treatment. 
2.0 METHODOLOGY 
2.1 Study area and population: The study was carried out 
among HIV positive patients on HAART attending HIV clinics 
in three selected hospitals from Imo State, South-East, 
Nigeria. They are; Imo State University Teaching Hospital 
Orlu, General Hospital Awo-omamma, and Imo State 
Specialist Hospital Umuguma, Owerri. Two of the hospitals 
(Imo State University Teaching Hospital Orlu and Imo State 
Specialist Hospital Umuguma) were located in urban area of 
the state while General hospital, Awo-omamma was located 
in a rural area. All of them are government owned hospitals 
and provide HIV care at all levels. 
The study population comprised all adult HIV patients on 
HAART attending clinics in the selected hospitals in the state. 
2.2 Study Design: The study was a hospital-based 
descriptive cross-sectional type. 
2.3 Selection Criteria: All HIV positive patients currently 
receiving anti-retroviral therapy at the clinics during the 
study period who consented to participate were enrolled and 
studied. 
Sample Size Estimation: The sample size of 400 patients 
was used for this study and this was determined using the 
Cochran sample size formula for cross-sectional studies in 
populations greater than 10,000 individuals. 
N=    Z2pq/ d2 
Where n= minimum sample size required, Z = standard 
normal deviate set at 95% significant level ≈1.96, p = 
prevalence of adverse reactions in a previous study (70%)20, 
q = 1-p, d = degree of precision set at 0.05. Also 10% attrition 
rate was added in the 400 sample size used. 
2.4 Sampling Technique: The respondents used in this 
study were selected using the multi stage sampling 
technique. 
The first stage involved the selection of the hospitals to be 
used. This was done by stratifying the hospitals that provide 
the HIV care in the state into secondary and tertiary health 
care providers. 
The second stage involved the selection of the hospitals to be 
studied. Two hospitals from the secondary category and one 
from the tertiary category were selected using simple 
random sampling by balloting based on number of hospitals 
in each category. 
The third stage involved the selection of the patients to be 
studied and this was done using the systematic random 
sampling technique and the clinic register. 
2.5 Data collection material: Information was collected 
from the respondents using a pretested, semi-structured, and 
interviewer administered questionnaire which comprised 
four sections. Section A contains questions bordering on 
socio-demographic characteristics of respondents. Section B; 
awareness and Knowledge about adverse drug reactions. 
Section C; drug use and occurrence of adverse drug reactions 
and section D; factors influencing adverse drug reactions 
among respondents. 
2.5 Data Analysis: Data was analyzed using a computer 
software (EPI INFO version 3.2:1) Descriptive statistics was 
presented in tables as frequencies and percentages. Chi 
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square test statistics was used to test significant associations 
between variables and logistic regression was used to 
generate odds ratios where necessary. Basic knowledge 
questions about adverse drug reactions were asked and 
scored as follows; 0-49% of the total as poor, 51-79% of the 
total as fair and >80% of the total as good knowledge. 
2. 6 Ethical approval: Ethical approval was gotten from the 
Ethics Committee of Imo State University Teaching Hospital 
Orlu before proceeding to study. The research was strictly 
conducted in line with laid down procedures as stated in 
Helsinki Declaration of 1964 in studies involving the use of 
human subjects. 
3.0 RESULTS 
Table3.1: Socio-demographic characteristics of 
participants. 
Variable  Frequency (%) n=400 
Age group (yrs) 
<20 22(5.4) 
20-29 81(20.3) 
30-39 108(27.0) 
40-49 108(28.7) 
≥50 81(20.3) 
Mean age=41.7±3.0  
Sex  
Male 133(33.2) 
Female 267(66.8) 
Religion  
Catholics  267(66.8) 
Pentecostals 111(27.8) 
Orthodox  17(4.2) 
Others1  5(1.2) 
Marital Status 
Ever married 303(75.8) 
Never married 97(24.2) 
Educational attainment  
None 7(1.7) 
Primary 77(19.3) 
Secondary 206(51.5) 
Tertiary 110(27.5) 
Occupational status  
Employed  309(77.3) 
Unemployed  91(22.7) 
Place of residence  
Rural  142(35.5) 
Urban  258(64.5) 
Others1 =Islam, Traditional religion and Paganism 
The mean age of the participants was 41.7±3.0 years with 
majority of them being within the 30-49 years age bracket, 
(54.0%). There were more females (66.8%) than males 
(33.2%), with a male to female ratio of 1:2. Majority of them 
were Catholics (66.8%), ever married (75.8%), had 
secondary education (51.5%), employed (77.3%) and lives in 
an urban area (64.5%). Table 3.1   
 
 
 
 
 
 
 
 
Table 3.2: Awareness and knowledge about adverse drug 
reactions among participants 
Variable  Frequency (%) 
Awareness about adverse drug reactions (n=400) 
Yes 374(93.5) 
No 26(6.5) 
**Sources of information (n=374) 
Radio 226(60.4) 
Health workers 219(58.6) 
Television 142(37.8) 
Chemist/pharmacy shop 101(27.0) 
Friends/neighbors/relatives 67(17.9) 
Newspapers/magazines 67(17.9) 
School 47(12.6) 
Work place 17(4.5) 
Billboards/posters 10(2.6) 
Seminar/workshops 7(1.8) 
Market  6(1.6) 
**Adverse drug reactions types mentioned (n=374) 
Skin manifestations(Rashes & itching)  332(88.8) 
GIT manifestations (Nausea, Vomiting 
and diarrhea) 
88(23.5) 
Headache  45(12.0) 
Drowsiness/Dizziness 19(5.1) 
Renal problems 17(4.5) 
Cough 15(4.0) 
Blurring of vision 14(3.7) 
Hearing defects/tinnitus 14(3.7) 
Numbness of the extremities 10(2.7) 
Yellowness of the eyes 10(2.7) 
Anaemia 5(5.3) 
Cardiovascular problems 3(0.8) 
Insomnia  3(0.8) 
Unconsciousness 2(0.3) 
Level of knowledge about adverse drug reactions (n= 
400) 
Poor (0-49%) 178(44.5) 
Fair (50-79%) 146(36.5) 
Good (≥80%) 76(19.0) 
**= multiple response 
Majority of the participants (93.5%), were aware about 
adverse drug reactions and the common sources of 
information were from; radio (60.4%), health workers 
(58.6%) and television (37.8%). The commonest adverse 
drug reaction mentioned were skin manifestations (88.8%), 
with more of them having poor (44.5%) or fair (36.5%) 
knowledge about adverse drug reactions. Table 3.2   
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Table 3.3: Adherence to anti-retroviral drugs and 
combination with other drugs 
Variable  Frequency (%) 
HIV treatment Regimen currently used (n=400) 
AZT+3TC+NVP 368(92.0) 
D4T+3TC+EFV 20(5.0) 
AZT+3TC+EFV 8(2.0) 
TDF+FTC+EFV 4(1.0) 
Adherence to HIV drugs (n=400) 
Yes  340(85.0) 
No  60(15.0) 
Frequency of non-adherence (n=60) 
2 or more times a week 50(83.3) 
Once weekly 8(13.3) 
At least once monthly 2(3.4) 
Main reason for missing dose (n=60) 
Forgot 40(66.7) 
Travelled  7(11.7) 
Tired of drug 5(8.3) 
Sick  3(5.0) 
Due to side effect 3(5.0) 
No reason 2(3.3) 
Combination with herbal drugs (n=400) 
Yes  22(5.5) 
No 378(94.5) 
Herbs commonly used (n=22) 
Aloe vera  6(27.3) 
Herbal concoction (Agbo) 6(27.3) 
Moringa (Drum stick leaf) 4(18.2) 
Dogoyaro (neem leaf) 4(18.2) 
Garlic 1(4.6) 
Ginger 1(4.6) 
Combination with other orthodox drugs (n=400) 
Yes  151(37.6) 
No  249(62.3) 
Combination with TB drugs (n=400) 
Yes 24(6.0) 
No 376(94.0) 
AZT: Zidovudine; 3TC: Lamivudine; NVP: Nevirapine; D4T: 
Stavudine; EFV: Evavirenz; TDF: Tenofovir; FTC: 
Emtricitabine.    
Majority of the participants (92.0%) were on AZT+3TC+NVP 
treatment regimen and adherence level among them was 
85.0%. Majority of those that were non-adherent to their 
drugs claim that they missed it more than once a week, 
(83.3%) and their main reason for not taking their drugs was 
that they forgot it (66.7%). A small proportion of the 
respondents (5.5%) combine their drug intake with herbs 
and common herbs used were; aloe vera, (27.3%), and 
herbal concoctions (27.3%). About 37.6% and 6.0% of the 
participants combine their drugs with other orthodox drugs 
and TB drugs respectively. Table 3.3 
 
 
 
 
 
 
 
Table 3.4: Occurrence and reporting of Adverse Drug 
Reactions (ADRs) among Participants 
Variable  Frequency (%) 
Ever experienced adverse drug reaction in your life 
time (n=400) 
Yes 146(36.5) 
No 254(63.5) 
Experience of ADRs while on HIV drug treatment in 
the last 1 year (N=400)  
Yes  55(13.7) 
No  345(86.2) 
**Forms of ADRs currently experienced (n=55) 
Anaemia  19(34.6) 
Nausea & Vomiting 11(20.0) 
Itching/ Rashes  11(20.0) 
Joint pain/Muscle weakness 10(18.2) 
Hallucinations 5(9.1) 
Peripheral Neuropathy/numbness  5(9.1) 
Renal impairment 4(7.3) 
Depression/ Insomnia 3(5.5) 
Confusion/ Prostration  2(3.6) 
Hearing impairment  1(1.8) 
Abdominal pain 1(1.8) 
Reported the reaction (n=55) 
Yes  53(96.4) 
No  2(3.6) 
Persons reported to (n=53) 
Doctor 42(79.3) 
Pharmacist 6(11.3) 
Nurse 5(9.4) 
**Actions taken by those reported to (n=53) 
Counseled me about the drug and its 
actions 
27(50.9) 
Asked me to continue the drug 19(35.9) 
Changed the drug regimen 15(28.3) 
Treated the reaction 4(7.6) 
Were you given the ADR form to fill (n=55) 
Yes 8(14.6) 
No  47(85.4) 
What was the fate of the ADR (n=55) 
Resolved spontaneously 43(78.2) 
Resolved over a long time 6(10.9) 
Resolved with some complications 3(5.5) 
Never resolved 3(5.5) 
**=Multiple response 
Table 3.4 showed the occurrence and reporting of ADRs 
among participants. The prevalence of ever experiencing 
ADRs among them was 36.5% and the current experience of 
ADRs while on anti-retroviral drugs was 13.7%. The common 
forms of ADRs experienced by respondents were; anaemia 
(34.6%), nausea and vomiting (20.0%), itching/rashes 
(20.0%). Most of the respondents (96.4%) claimed to have 
reported the ADR to a caregiver, with majority of them 
(79.3%) reporting it to their physicians. Common actions 
taken by those reported to were; counselling about the drug 
(50.9%) and encouraging them to continue with the drugs 
(35.9%). Most of those that had adverse reaction did not fill 
the ADR forms, (85.4%) and majority of them (78.2%), 
claiming that the reactions resolved spontaneously.
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Table 3.5: Socio-demographic Determinants of the occurrence of ADRs among participants 
Variable           Occurrence of adverse drug reaction Statistics (X2) 
P-value  
OR (95% CI) 
Yes (%) No (%) Total (%) 
Age group (yrs) 
< 50 22(6.9) 297(93.1) 319(100) 62.235 1.00 
>50 33(40.7) 48(59.3) 81(100) P<0.0001* 9.28* (4.99-17.25) 
Total  55(13.7) 345(86.3) 400(100)   
Sex 
Male 9(6.8) 124(93.2) 133(100) 8.192 1.00 
Female 46(17.2) 221(82.8) 267(100) p=004* 2.55* (1.28-5.04) 
Total 55(13.7) 345(86.3) 400(100)   
Marital status 
Ever married 38(12.5 265(87.5) 303(100) 1.539 1.00 
Never married 17(17.5) 80(82.5) 97(100) p=0.215 1.40 (0.83-2.36) 
Total 55(13.7) 345(86.3) 400(100)   
Educational level 
≤ secondary 40(13.8) 250(86.2) 290(100) 0.002 1.00 
Tertiary 15(13.6) 95(86.4) 110(100) p=0.968 0.99 (0.52-1.87) 
Total 55(13.7) 345(86.3) 400(100)   
Occupational status 
Employed  47(17.9) 262(82.1) 309(100) 2.443 1.73 (0.85-3.53) 
Unemployed  8(8.8) 83(91.2) 91(100) p=0.118 1.00 
Total  55(13.7) 345(86.3) 400(100)   
Place of residence 
Urban  19(7.4) 239(92.6) 258(100) 24.999 1.00 
Rural 36(25.4) 106(74.7) 142(100) P<0.0001* 4.27* (2.34-7.79) 
Total  55(13.7) 345(86.3) 400(100)   
*=significant 
Socio-demographic factors found to be associated with the 
occurrence of adverse drug reactions as reported by the 
participants were; age (X2=62.235, p<0.0001), sex 
(X2=8.192, p=0.004), and place of residence (X2=24.999, 
p<0.0001). The likely predictors of the occurrence of an 
adverse drug reaction as reported by the patients were; 
being at age ≥ 50 years (OR: 9.28), a female (OR: 2.55), and 
living in a rural area, (OR: 4.77).   
4.0 DISCUSSION 
Despite great success recorded in the management of 
HIV/AIDS globally with the introduction of HAART, adverse 
drug reactions associated with the drugs has been an 
impediment in the overall care of HIV/AIDs patients.  This is 
worrisome in that it leads to reduced adherence to HIV/AIDs 
treatment with its attendant problems.  Thus our study 
sought to determine the prevalence of ADRs and associated 
socio-demographic factors among patients on antiretroviral 
therapy irrespective of the time initiation of treatment. 
The prevalence of ADRs as revealed in our study was 13.7%.  
This was higher than figures report from Nicaragua 
(6.45%)30 and Ghana (9.4%)38 but lower than reports from 
several other studies. 14,20,32,33,36,37  This low prevalence 
reported from our work could be associated to a lot of 
factors ranging from method of data collection and materials 
used, to host and environmental factors.  The prevalence 
was calculated for the year preceding the survey and by that 
time, some of the old patients may have been stable on 
treatment and may not be having ADRs or might also have 
forgotten if it actually occurred. It could be connected to low 
level of knowledge about ADR’s that was found among the 
participants. Common ADR’s reported in this study were; 
hematological manifestations GIT manifestations, 
Dermatological manifestations and CNS manifestations.  This 
pattern of manifestation was similar to findings reported 
from several studies.10,11,20,33,34,36 It is also worthy to note 
that this pattern of ADRs reported was similar to the 
common side effects associated with major HAART regimen 
used by most of the patients (zudovudine + Lanuvudine 
+Nevirapine).  There is a likelihood that some mild ADRs 
may not have been reported by the patients nor found by the 
researchers due to their similarity with the symptoms and 
signs of HIV infection which further supports the low 
prevalence rate reported from the study. 
Socio-demographic factors that were formed to be 
associated with the occurrence of ADRs among the 
participants were: age of patient, sex of patient and place of 
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residence.  Patients 50 years and above had a higher 
likelihood of developing ADR than those below 50 years of 
age.  This pattern of association with age has been reported 
in previous studies.19,22 Nevertheless, many other studies 
reported no association with age.14,33,38,39,40  Age has been 
noted to be a very important factor which affects the 
occurrence of ADRs generally and older people have been 
reported to be more than twice at risk of developing an ADR 
than the younger people.8,41 It has been reported that as 
people get older, the liver loses the ability to metabolize 
drugs. Aging also affects other organs that help in drug 
metabolism and excretion thus leaving higher 
concentrations in the body fluid which could dispose them to 
having ADR.  This can be supported by the fact that many 
older people are likely to have many health problems and 
thus take several prescriptions which could lead to drug 
interactions and adverse effects.   
Our study revealed that females were more than twice likely 
to develop an ADR than their male counterparts.  Sex 
difference in ADRs occurrence to antiretroviral drugs has 
been reported from other studies.8,10,19,38,43  This could be 
accounted for by the biological differences between males 
and females which affects the action of many drugs.  There 
are differences in body weight, body composition, 
gastrointestinal tract functions, liver metabolism and renal 
function etc.  Women when compared to men, have lower 
body weight and organ size, more body fat, different gastric 
motility, lower glomerular filtration rate and more active 
hepatic enzyme CY3A4 which may lead to different effects 
on drug metabolism.8, 44. 
Place of residence of the patients was associated with the 
occurrence of ADRs with those living in the rural areas being 
more likely to have an ADR to antiretroviral therapy than 
their urban counterparts.  Though no study was seen to 
report an association with residency of people, some studies 
found a relationship between employment status and 
occupation with the occurrence of ADR.33,39  One of the 
studies further showed that the unemployed, students and 
petty traders to be more likely to develop ADR than others.  
This association could be linked to psychosocial problems 
caused by poverty and other related problems not 
necessarily due to a direct link with antiretroviral drug 
intake. 
It is worthy to note that there was no significant association 
found in this study between religion, marital status, 
educational attainment and employment status of 
participants with the occurrence of ADRs. This corroborates 
with finding from previous studies.14,33,38,39  
Study limitation 
This study finding was a self-reported type and the 
prevalence of ADRs could have been under or over reported. 
Furthermore no laboratory investigations or other 
diagnostic test for ruling out other causes were implored.  
The reporting could also be influenced by the patient’s 
ability to memorize events related to ADRs.  Thus caution 
should be taken in generalizing the findings of this research. 
CONCLUSION 
Our study showed a low knowledge about ADRs and also a 
low prevalence of the occurrence of ADRs among the 
patients on HAART in the studied facilities in the State.  We 
also observed a low level of adherence when compared to 
the general cut off of 95% adherence and predictors of 
occurrence of ADRs found in this study were female gender, 
older age group and living in the rural areas of the state.  
There is therefore need to create awareness about ADRs 
among patients of HAART in the state by making patient 
education a key part of HIV/AIDS treatment. 
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